De‐intensification of basal‐bolus therapy by replacing prandial insulin with once‐weekly subcutaneous semaglutide in individuals with well‐controlled type 2 diabetes: A single‐centre, open‐label randomised trial ( TRANSITION ‐ T2D )
Authors' conclusion
In people with type 2 diabetes well controlled (HbA1c ≤7.5% [≤58 mmol/mol]) on MDI ≤120 units/day, replacing multiple daily injections of prandial insulin with once-weekly subcutaneous semaglutide can maintain and even improve HbA1c, lower body weight and lessen the burden of management.
Study context
- Population
- Adults with T2D, HbA1c ≤7.5% (58 mmol/mol) on MDI with total daily dose (TDD) ≤120 units/dayrandomised 2:1
- Participants
- 60 adults
- Comparison
- Semaglutide 1.0 mg plus insulin degludec vs continued MDI
- Primary endpoint
- Percentage of subjects maintaining HbA1c ≤7.5% (58 mmol/mol)
- Follow-up
- Week 26
Methodological detailssingle-centre, open-label, 2:1 allocation
- Single-centre
- Open-label
- 2:1 allocation
Primary result
As reported in the abstract
HbA1c ≤7.5% (≤58 mmol/mol) maintained
P = 0.18
Further findings
| Outcome | Semaglutide | MDI | P value |
|---|---|---|---|
| Mean change in HbA1c% | −0.5 (95% CI −0.7–-0.3) | 0.0 (95% CI −0.3–0.3) | P = 0.009 |
| Mean change in weightkg | −8.9 (95% CI −9.9–-7.8) | 1.5 (95% CI −0.1–3.1) | P < 0.001 |
| Mean change in percentage body weight% | −8.6 (95% CI −9.6–-7.6) | 1.4 (95% CI 0.0–2.8) | P < 0.001 |
| Change in insulin TDDDecreased with semaglutide; increased with MDI | 56.0% (CI −62.3–-49.7) | 6.7% (CI −2.5–16.0) | P < 0.001 |
Semaglutide group outcomes
- Reduced insulin TDD >50%
- 58%
- Stopped prandial insulin
- 97.5%
- Lost >10% body weight
- 45%
Treatment satisfaction
- Participant treatment satisfaction scores trended higher with semaglutide
Safety
- Hypoglycaemia frequency was similar between groups
Original publication
De‐intensification of basal‐bolus therapy by replacing prandial insulin with once‐weekly subcutaneous semaglutide in individuals with well‐controlled type 2 diabetes: A single‐centre, open‐label randomised trial ( TRANSITION ‐ T2D ). Diabetes Obes Metab. Published 12 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →